Stock A950200 PSOMAGEN, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Psomagen, Inc.

Equities

A950200

KR8840150005

Biotechnology & Medical Research

End-of-day quote Korea S.E.
Other stock markets
 23:00:00 30/05/2024 BST 		5-day change 1st Jan Change
4,755 KRW +0.63% Intraday chart for Psomagen, Inc. +0.85% -6.76%
03-18 The Global Parkinson's Genetics Program and Psomagen Inc. Make Agreement with Goal to Transform Parkinson's Disease Genetics Research and Patient Outcomes CI
2023 Psomagen Announces the Launch of Spatial Biology Services for 10X Genomics Xenium?? CI

Valuation

Fiscal Period: December 2022 2023
Capitalization 1 149,031 98,104
Enterprise Value (EV) 1 139,324 92,073
P/E ratio -142 x -22.9 x
Yield - -
Capitalization / Revenue 3.44 x 3.04 x
EV / Revenue 3.21 x 2.85 x
EV / EBITDA 58.7 x 218 x
EV / FCF - -28,999,508 x
FCF Yield - -0%
Price to Book 3.27 x 3.04 x
Nbr of stocks (in thousands) 19,205 19,236
Reference price 2 7,760 5,100
Announcement Date 21/03/24 21/03/24
1KRW in Million2KRW
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2022 2023
Net sales 1 43,374 32,275
EBITDA 1 2,372 422
EBIT 1 -1,475 -3,553
Operating Margin -3.4% -11.01%
Earnings before Tax (EBT) 1 -1,042 -4,384
Net income 1 -1,048 -4,288
Net margin -2.42% -13.29%
EPS 2 -54.72 -223.1
Free Cash Flow - -3,175
FCF margin - -9.84%
FCF Conversion (EBITDA) - -
FCF Conversion (Net income) - -
Dividend per Share - -
Announcement Date 21/03/24 21/03/24
1KRW in Million2KRW
Estimates

Balance Sheet Analysis

Fiscal Period: December 2022 2023
Net Debt 1 - -
Net Cash position 1 9,707 6,031
Leverage (Debt/EBITDA) - -
Free Cash Flow - -3,175
ROE (net income / shareholders' equity) - -12.9%
ROA (Net income/ Total Assets) - -4.73%
Assets 1 - 90,583
Book Value Per Share 2 2,370 1,675
Cash Flow per Share 2 988.0 157.0
Capex 1 2,735 4,804
Capex / Sales 6.31% 14.89%
Announcement Date 21/03/24 21/03/24
1KRW in Million2KRW
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
PSOMAGEN, INC. Stock Psomagen, Inc.
-6.76% 66.14M
MODERNA, INC. Stock Moderna, Inc.
+43.36% 54.64B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-5.31% 39.92B
LONZA GROUP AG Stock Lonza Group AG
+37.52% 38.82B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+14.75% 26.86B
CELLTRION, INC. Stock Celltrion, Inc.
-12.56% 26.22B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-22.45% 18.78B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
+0.04% 12.16B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+25.12% 12.21B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+26.04% 11.94B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. A950200 Stock
  4. Financials Psomagen, Inc.